Free the Slaves is pleased to announce that philanthropist, business strategist and biotech executive Daniel Elkes has joined the FTS board of directors.
Dan currently works in the biotechnology industry as the director of the pipeline and portfolio planning group at Genentech, where he uses his expertise in strategic planning, decision analysis and pharmaceutical development to help guide work developing treatments for life threatening diseases. He was previously employed at Medarex, where he was part of the team that developed a revolutionary immunotherapy for oncology, and has also served as a management consultant.
Dan received his Ph.D. in genetics from Harvard University, and earned a Certificate in Public and International Affairs from his undergraduate studies at Princeton University, where he graduated with an A.B. in molecular biology. He has a strong background in Japanese culture and language, and learned Japanese and studied Japanese business practices at Matsushita Electric in Hirakata, Japan.
“I am delighted that Dan has decided to join the board,” says FTS Executive Director Maurice Middleberg. “He brings a great passion for eradicating slavery and a superb, diverse set of skills, including a remarkable capacity for thinking long-term and strategically. His commitment and ability to “think big” will be great assets to Free the Slaves.
“We are pleased to welcome Dan to the board,” says FTS Board Chair Jane Covey. “He brings deep personal commitment to ending slavery as well as strategic thinking, both of which enhance our capacity to govern effectively.”
Dan has a passion for service and has dedicated his career to the mission of improving the quality of life for those around him. He serves as a trustee of the Elkes Foundation and lives in San Carlos California with his wife and three children.
